Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Ticker
TEVA
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market cap
$49.72B
52-week range
$23.61 - $43.34

Valuation

Share price
$42.61 (close of Nov 6, 2026)
P/E (TTM)
94.69x
Price to book
6.23x
Price to free cash flow
40.26x
Enterprise value
$62.62B
Book value per share
$6.84

Price performance

PeriodChange
1 day+1.99%
5 days+1.24%
1 month+8.89%
3 months+22.41%
6 months+17.25%
Year to date+36.53%
1 year+74.20%
3 years+370.83%
5 years+366.70%
10 years+5.89%
All time+4,601.79%

Short interest

As of
Oct 15, 2026
Short % of float
2.42%
Shares short
28.07M
Days to cover
3.92
Change since prior report
-5.96%
Source
FINRA consolidated short interest

Members of Congress who disclosed TEVA trades

Alan Armstrong

Super investors holding TEVA

Harry Burn (Sound Shore Management) · David Einhorn (DME Capital Management) · Ray Dalio (Bridgewater Associates) · Stanley Druckenmiller (Duquesne Family Office) · Ken Griffin (Citadel)

Profitability and growth

Return on equity
17.82%
Return on invested capital
8.63%
Return on assets
3.46%
Return on capital employed
7.90%
Gross margin
51.79%
Net margin
8.17%
EBITDA margin
18.30%
Revenue growth
4.32%
Free cash flow growth
53.27%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.48%
Current ratio
0.95x
Net debt to EBITDA
5.84x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$17.26B
Cost of revenue
$8.32B
Gross profit
$8.94B
EBITDA
$3.16B
Net income
$1.41B
Earnings per share
$1.23
Research and development
$1.01B
Interest expense
$916.00M
Shares outstanding
1.15B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$17.26B$8.94B$1.41B$1.23
2024-12-31$16.54B$8.06B-$1.64B-$1.45
2023-12-31$15.85B$7.64B-$559.00M-$0.50
2022-12-31$14.93B$6.97B-$2.45B-$2.20
2021-12-31$15.88B$7.59B$417.00M$0.38
2020-12-31$16.66B$7.73B-$3.99B-$3.64
2019-12-31$16.89B$7.54B-$999.00M-$0.91
2018-12-31$18.27B$8.30B-$2.15B-$2.35
2017-12-31$21.85B$10.62B-$16.27B-$16.26
2016-12-31$21.90B$11.65B$329.00M$0.07

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3151.79%8.17%17.82%8.63%
2024-12-3148.74%-9.91%-30.46%-1.29%
2023-12-3148.25%-3.53%-6.88%1.53%
2022-12-3146.72%-16.39%-28.45%-5.15%
2021-12-3147.83%2.63%3.71%11.13%
2020-12-3146.38%-23.95%-36.07%-22.35%
2019-12-3144.63%-5.92%-6.63%-1.21%
2018-12-3145.41%-11.77%-13.61%-8.01%
2017-12-3148.57%-74.43%-86.77%-30.36%
2016-12-3153.20%1.50%0.94%2.31%

Cash and debt by year

Period endCashDebt
2025-12-31$3.56B-
2024-12-31$3.30B-
2023-12-31$3.23B-
2022-12-31$2.80B-
2021-12-31$2.17B-
2020-12-31$2.18B-
2019-12-31$1.98B-
2018-12-31$1.78B-
2017-12-31$963.00M$28.83B
2016-12-31$988.00M$32.52B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.15B$157.00M
2024-12-31$749.00M$123.00M
2023-12-31$842.00M$121.00M
2022-12-31$1.04B$124.00M
2021-12-31$236.00M$119.00M
2020-12-31$638.00M$129.00M
2019-12-31$223.00M$119.00M
2018-12-31$1.79B$155.00M
2017-12-31$1.35B$133.00M
2016-12-31$2.99B$124.00M

Dividend history

Most recent payment
Nov 27, 2017
Payment dateDividend per share
2017-11-27$0.09
2017-08-25$0.09
2017-06-01$0.34
2017-02-28$0.34
2016-12-01$0.34
2016-08-18$0.34
2016-05-20$0.34
2016-02-25$0.34

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-03Sep 2026$0.70
2026-07-29Jun 2026$0.05
2026-04-29Mar 2026$0.49
2026-01-28Dec 2025$0.63
2025-11-05Sep 2025$0.66
2025-07-30Jun 2025$0.60
2025-05-07Mar 2025$0.47
2025-01-29Dec 2024$0.66

Filings and sources

Company website
tevapharm.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Novo Nordisk A S (NVO) · GSK plc (GSK) · Organon & Co. (OGN) · Biogen Inc. (BIIB)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades